- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01719107
Efficacy of Dietary Supplementation With Lactobacilllus Reuteri DSM 17938 on Functional Abdominal Pain (FAP) in Children
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, double-blind, placebo-controlled study. Subjects between of 5-16 years of age with FAP as defined in the Rome III criteria and with pain severity of at least 40 mm on a 100 mm VAS scale and pain frequency of at least 1 episode per week over the preceding 8 weeks will be recruited. In accordance to the specific Rome III criteria for inclusion, FAP is defined as a variable combination of chronic or recurrent gastrointestinal symptoms not explained by structural or biochemical abnormalities.
A study questionnaire to record pain and other gastrointestinal symptoms will be used.
One-hundred and six (106) Subjects will be randomized to receive either dietary supplementation with L. reuteri DSM 17938 (2 chewable tablets with breakfast), or the same number of comparable placebo tablets, for 4 weeks. Supplementation will be stopped after 4 weeks, and the subjects will be followed up for an additional 4 weeks. The subjects will complete a diary to record frequency and intensity of pain, use of medication, deviation from the usual diet, physical activities, and absence from school and other activities. Gastrointestinal symptoms are assessed by the GSRS (Gastrointestinal Symptom Rating Score).
Subjects/caregivers will be instructed to maintain the usual diet throughout the study, but not to consume other probiotics (foods or supplements) during the entire study period.
The symptoms diary will be completed daily by the parents and will report information on the frequency of pain episodes, location of pain, presence or absence of associated symptoms, need to take medication for pain and interference with normal activities. The intensity of the symptoms will be assessed by using the Wong-Baker Faces scale.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects will be recruited according to the following inclusion criteria:
- FAP (Functional Abdominal Pain) according to Rome III criteria for Child/Adolescent; 1 or more abdominal pain episodes per week over the past 8 weeks
- Informed consent by study participant and at least one parent/legal guardian;
- Age of 5-16 years;
- Pain severity at study entry must be at least 40 mm on a 100 mm VAS scale;
- Pain frequency of at least 1 or more episodes per week over the preceding 8 weeks;
- Ability to understand and comply with the requirements of the trial;
- Stated availability throughout the study period
Exclusion Criteria:
Subjects presenting with one or more of the following criteria will be excluded from participation in the study:
- Chronic illness;
- Surgery of gastrointestinal tract
- Any symptoms/signs of organic disease and/or any abnormal results of laboratory assays (total blood count, serum glucose, urea, electrolytes, amylase, SGOT, SGPT, anti tTG antibodies, breath H2 test, suggesting disease other than FAP;
- Weight loss of 5% or more in body weight over the preceding 3 months;
- Exposure to any drugs for FAP in the past 2 weeks.
- Exposure to probiotics or antibiotics within 4 weeks prior to study; subjects can be included following a wash-out period of 4 weeks.
- Participation in other interventional clinical trials in the past 3 months;
- Subjects with special dietary needs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: L. reuteri DSM 17938 chewable tablets
The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938.
The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots.
It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
The total viable count of L. reuteri DSM 17938 is 1x108 live bacteria (CFU)/tablet.
|
2 chewable tablets with breakfast for 4 weeks
|
PLACEBO_COMPARATOR: Placebo chewable tablets
The placebo study product consists of an identical formulation in all respects except that the live bacteria are excluded.
|
2 chewable tablets with breakfast for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Abdominal pain frequency and severity over the 4-week treatment period.
Time Frame: 4 weeks
|
Reduction in pain frequency measured by a subject diary, in the L. reuteri DSM 17938 group and the placebo group, expressed as area under the pain-frequency curve and comparing L. reuteri DSM 17938 vs placebo over the treatment period. Reduction in pain severity is assessed using the face score system of Wong-Baker at day 14 and at the end of treatment (day 28)vs. baseline. Area under the pain-intensity curve will be assessed for Weeks 1-4 and Weeks 1-2 |
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in pain frequency and intensity over the 8-week study period
Time Frame: 8 weeks
|
Reduction in pain frequency measured by a subject diary in the L. reuteri group expressed as area under the L. reuteri pain-frequency curve compared to placebo over the initial 2 weeks of the treatment period as well as over the whole study period. Reduction in pain intensity, measured by the face score system of Wong-Baker at day 14, end of treatment (day 28), and end of follow-up period (day 56) vs baseline. Area under the pain-intensity curve for Weeks 1-4 and Weeks 1-2 will be compared. |
8 weeks
|
Reduction in other GI symptoms over the whole study period
Time Frame: 8 weeks
|
Reduction in other GI symptoms as measured by Gastrointestinal Symptom Rating Scoring system.
Time points: baseline, day 14, end of treatment and end of follow-up, in the L. reuteri group vs. placebo.
|
8 weeks
|
Days of absence from school and other activities due to abdominal pain over the whole study period
Time Frame: 8 weeks
|
The number of days of absence from school and other activities due to abdominal pain will be compared between the L. reuteri group vs placebo.
|
8 weeks
|
Reduction in absence from work by parents over the whole study period
Time Frame: 8 weeks
|
he number of days of absence from work by parents due to abdominal pain of the child will be compared between the L. reuteri group vs placebo.
|
8 weeks
|
Safety outcome over the whole study period
Time Frame: 8 weeks
|
The number of adverse events will be observed and recorded during the entire study period
|
8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Alexandra Papadopoulou, Hon. Prof. Dr. med., Athens Interconnected Children's Hospitals "AGIA SOPHIA" and "P & A KYRIAKOU"
- Principal Investigator: Hania Szajewska, Prof, Warsaw University
- Principal Investigator: Rok Orel, Ass. Prof., Ljubljana University
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSUB0003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Abdominal Pain (FAP) in Children
-
Baylor College of MedicineUniversity of WashingtonRecruitingIrritable Bowel Syndrome | Functional Abdominal Pain | Functional Gastrointestinal Disorders | Functional Abdominal Pain Syndrome | Functional Bowel Disorder | Functional Abdominal Pain DisordersUnited States
-
Dr Anne PayneUniversity of LondonUnknownFunctional Gastrointestinal Disorders in ChildrenUnited Kingdom
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedFunctional Gastrointestinal Disorders | Functional Abdominal Pain Syndrome | Abdominal Pain (AP)
-
Amal Fathy Abo ElgaradUnknown
-
Boston Children's HospitalNationwide Children's HospitalCompletedFunctional Dyspepsia | Irritable Bowel Syndrome | Functional Abdominal Pain | Functional Gastrointestinal DisordersUnited States
-
PrecisionBiotics Group Ltd.Instituto de Nutrición y Tecnología de los AlimentosCompletedFunctional Abdominal Pain | Functional Gastrointestinal DisordersChile
-
Duke UniversityUnknown
-
Children's Mercy Hospital Kansas CityUniversity of ArizonaCompletedFunctional Abdominal Pain
-
Assiut UniversityUnknownFunctional Abdominal Pain Syndrome
Clinical Trials on L. reuteri DSM 17938 chewable tablets
-
Innovacion y Desarrollo de Estrategias en SaludBioGaia ABCompletedIrritable Bowel SyndromeChile, Mexico
-
University of CopenhagenCompleted
-
Lama Medical Care s.r.o.BioGaia ABUnknownDyspepsia | H. Pylori InfectionSlovakia
-
Malo ClinicCompletedPeri-implant MucositisPortugal
-
Shanghai Children's HospitalShanghai Children's Medical Center; BioGaia AB; Suzhou University Affiliated...UnknownCrying Time in Colicky InfantsChina
-
Azienda Ospedaliera Specializzata in Gastroenterologia...Completed
-
University of CopenhagenCompletedPeriodontitis | Dental CariesDenmark
-
University of CopenhagenKarolinska InstitutetCompleted
-
University of CopenhagenHalmstad County HospitalUnknownPostoperative Complications
-
Innovacion y Desarrollo de Estrategias en SaludBioGaia ABUnknown